deltatrials
Not Yet Recruiting OBSERVATIONAL NCT06823050

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced Hepatocellular Carcinoma with the DEB-TACE (drug-loaded Microsphere Transcatheter Arterial Chemoembolization) Combined with Hepatic Artery Perfusion of Raltitrexed and Oxaliplatin (SALOX-HAIC) Regimen

Sponsor: Xuhua Duan

Conditions Hepatocellular Carcinoma
Updated 2 times since 2025 Last updated: Feb 7, 2025 Started: Mar 1, 2025 Primary completion: Mar 1, 2026 Completion: Feb 28, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hepatocellular Carcinoma and is currently actively recruiting participants. Xuhua Duan leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshotNot Yet Recruiting~Sep 2025 – present · 10 months · monthly snapshotNot Yet Recruiting

Change History

2 versions recorded

  1. Sep 2025 — Present [monthly]

    Not Yet Recruiting

  2. Mar 2025 — Sep 2025 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Xuhua Duan
Data source: The First Affiliated Hospital of Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations